Currently, for pancreatic cancer, combination therapy including TLR9-activating CpGs is being evaluated in two clinical trials (Clinicaltrials.gov accessed on 28 October 2021: # NCT04612530 and # NCT04050085). This evidence concerns the gene TLR9 and familial pancreatic carcinoma.